Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, 1050 Wishard Blvd., RG 5, Indianapolis, IN, 46202, USA.
Division of Infectious Disease, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
BMC Pregnancy Childbirth. 2021 Oct 30;21(1):739. doi: 10.1186/s12884-021-04211-8.
The number of congenital syphilis (CS) cases in the United States are increasing. Effective prevention of CS requires routine serologic testing and treatment of infected pregnant women. The Centers for Disease Control and Prevention (CDC) recommends testing all pregnant women at their first prenatal visit and subsequent testing at 28 weeks gestation and delivery for women at increased risk.
We conducted a cross-sectional cohort study of syphilis testing among pregnant women with a livebirth delivery from January 2014 to December 2016 in Marion County, Indiana. We extracted and linked maternal and infant data from the vital records in a local health department to electronic health records available in a regional health information exchange. We examined syphilis testing rates and factors associated with non-testing among women with livebirth delivery. We further examined these rates and factors among women who reside in syphilis prevalent areas.
Among 21260 pregnancies that resulted in livebirths, syphilis testing in any trimester, including delivery, increased from 71.7% in 2014 to 86.6% in 2016. The number of maternal syphilis tests administered only at delivery decreased from 16.6% in 2014 to 4.04% in 2016. Among women living in areas with high syphilis rates, syphilis screening rates increased from 79.6% in 2014 to 94.2% in 2016.
Improvement in prenatal syphilis screening is apparent and encouraging, yet roughly 1-in-10 women do not receive syphilis screening during pregnancy. Adherence to recommendations set out by CDC improved over time. Given increasing congenital syphilis cases, the need for timely diagnoses and prevention of transmission from mother to fetus remains a priority for public health.
美国先天性梅毒(CS)病例数量正在增加。有效预防 CS 需要对感染孕妇进行常规血清学检测和治疗。疾病控制与预防中心(CDC)建议所有孕妇在首次产前检查时进行检测,并在妊娠 28 周和分娩时对高危孕妇进行后续检测。
我们对印第安纳州马里恩县 2014 年 1 月至 2016 年 12 月期间活产分娩的孕妇进行了一项梅毒检测的横断面队列研究。我们从当地卫生部门的生命记录中提取并链接了母婴数据,并将其与区域卫生信息交换中可获得的电子健康记录进行关联。我们检查了活产分娩孕妇的梅毒检测率和未检测的相关因素。我们进一步检查了居住在梅毒流行地区的孕妇的这些检测率和因素。
在 21260 例活产妊娠中,任何孕期(包括分娩时)的梅毒检测率从 2014 年的 71.7%增加到 2016 年的 86.6%。仅在分娩时进行的母体梅毒检测数量从 2014 年的 16.6%下降到 2016 年的 4.04%。在梅毒发病率较高的地区,梅毒筛查率从 2014 年的 79.6%增加到 2016 年的 94.2%。
产前梅毒筛查的改善是明显且令人鼓舞的,但仍有约 1/10 的孕妇在怀孕期间未接受梅毒筛查。随着时间的推移,对 CDC 建议的遵循有所改善。鉴于先天性梅毒病例不断增加,及时诊断和预防母婴传播仍然是公共卫生的重点。